Article
Oncology
Tsuyoshi Isawa, Yukihiro Toi, Shunichi Sugawara, Masataka Taguri, Shigeru Toyoda
Summary: This study evaluates the incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events (CV-irAEs), and finds that CV-irAEs are more common than previously recognized. Serial cardiac monitoring can predict future grade >= 2 CV-irAEs.
Article
Immunology
Janice K. Louie, Chris Keh, Rocio Agraz-Lara, Allison Phillips, Susannah Graves
Summary: This study found that a significant proportion of patients being treated for drug-susceptible tuberculosis experienced moderate to severe adverse events that required treatment interruption or changes in drug regimens, with the elderly being more affected. Therefore, there is a need for safer and more effective treatment options.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Cardiac & Cardiovascular Systems
Michael G. Fradley, Nam H. K. Nguyen, David Madnick, Yiqing Chen, Angela DeMichele, Igor Makhlin, Susan Dent, Benedicte Lefebvre, Joseph Carver, Jenica N. Upshaw, David DeRemer, Bonnie Ky, Avirup Guha, Yan Gong
Summary: Patients with hormone receptor-positive metastatic breast cancer treated with CDK4/6 inhibitors have a higher incidence of cardiovascular adverse events, particularly atrial fibrillation/flutter and heart failure/cardiomyopathy. Further research is needed to investigate the association between these novel anticancer treatments and cardiovascular risk.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Microbiology
A. J. Berenstein, N. Falk, G. Moscatelli, S. Moroni, N. Gonzalez, F. Garcia-Bournissen, G. Ballering, H. Freilij, J. Altcheh
Summary: The study found that adverse drug reactions (ADRs) associated with Nifurtimox treatment for Chagas disease were relatively rare and mainly mild to moderate. ADRs primarily affected the nutritional, central nervous, and digestive systems, with no significant differences between adults and children. The proportion of treatment discontinuations due to ADRs was higher in adults compared to children.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Oncology
P. Vallerio, A. Orenti, F. Tosi, M. Maistrello, M. Palazzini, S. Cingarlini, P. Colombo, M. Bertuzzi, F. Spina, A. Amatu, R. Lombardo, I Prata, F. Scaglione, G. D. Vighi, B. Severgnini, S. Siena, C. Giannattasio, P. Boracchi, A. Sartore-Bianchi
Summary: MACEs occur in a clinically significant proportion of patients treated with VEGFR-targeted TKIs, with ATEs being predominant, mainly associated with hypertension and dyslipidemia. The presence of previous MACEs is also a risk factor for all MACEs.
Article
Cardiac & Cardiovascular Systems
Chuan Zhang, Zhulu Chen, Shu Qin, Yuxi Zhu, Linjie Shu, Zhong Zuo
Summary: This study investigated the incidence and risk factors of immune checkpoint inhibitors (ICI)-related adverse cardiovascular events (ACEs) and left ventricular dysfunction (LVD) caused by ICI. The results showed that patients treated with ICI may develop multiple ACEs, including acute myocarditis, pericarditis, ECG abnormalities, and elevated cardiac biomarkers. The incidence of LVD is high after ICI treatment, and echocardiography is helpful for early detection. Hypertension or poor LV systolic or diastolic function at baseline are predictors of LVD after ICI treatment.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Review
Oncology
Maryam B. Lustberg, Nicole M. Kuderer, Aakash Desai, Cristiane Bergerot, Gary H. Lyman
Summary: Despite the lack of systematic efforts, this review provides a comprehensive analysis of the most common long-term and late adverse events associated with chemotherapy and other anticancer treatments. It discusses the underlying mechanisms, management strategies, and clinical practice guidelines for these adverse events. Additionally, it highlights the need for effective management of treatment-related events in oncology.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Toxicology
Michael Simpson, Andrew Troger, Chris Feng, James D. D. Whitledge, Michael Monuteaux, Michele M. M. Burns
Summary: This study aimed to identify factors associated with adverse cardiovascular events in adult patients with isolated bupropion exposures. Increasing age, seizures, QRS widening, and QTc prolongation were independently associated with adverse cardiovascular events. Adverse cardiovascular events did not occur in unintentional exposures.
CLINICAL TOXICOLOGY
(2023)
Article
Oncology
Avirup Guha, Prantesh Jain, Michael G. Fradley, Daniel Lenihan, Jahir M. Gutierrez, Chhavi Jain, Marcos de Lima, Jill S. Barnholtz-Sloan, Guilherme H. Oliveira, Afshin Dowlati, Sadeer Al-Kindi
Summary: In comparison to monotherapy with BRAF inhibitors, combination therapy with BRAF/MEK inhibitors is associated with increased cardiovascular adverse events (CVAEs), primarily heart failure (HF) and hypertension, as confirmed in two independent real-world cohorts.
Article
Pharmacology & Pharmacy
Hui Zhao, Jun-Min Li, Zi-Ran Li, Qian Zhang, Ming-Kang Zhong, Ming-Ming Yan, Xiao-Yan Qiu
Summary: A study found that testosterone replacement treatment (TRT) may increase the risk of cardiovascular events such as myocardial infarction and cardiomyopathy in men. However, TRT showed beneficial effects in populations with conditions such as testosterone deficiency, diabetes mellitus, and hypertension. These cardiovascular events are rare but have serious consequences.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Bin Lu, Longfei Shen, Ying Ma, Jia Qi, Yulin Li, Zhihao Wang, Lu Han, Ming Zhong
Summary: This systematic review and meta-analysis evaluated the risk of cardiotoxicity and efficacy associated with the (R)-CDOP regimen in patients with non-Hodgkin's lymphoma. The findings showed that compared with the conventional anthracycline-based (R)-CHOP regimen, the (R)-CDOP regimen had a lower risk of cardiovascular adverse events and demonstrated similar efficacy in the treatment of non-Hodgkin's lymphoma.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Anne M. Butler, Michael J. Durkin, Matthew R. Keller, Yinjiao Ma, William G. Powderly, Margaret A. Olsen
Summary: In the treatment of uncomplicated UTI in commercially insured women, nitrofurantoin has lower risks of adverse drug events and potential microbiome-related adverse events compared to other agents. The duration of treatment modifies the risk of potential microbiome-related adverse events.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Linyang Gan, Huan Chen, Xiaowei Liu, Li Zhang
Summary: This study investigated the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor therapy and reported the clinical features, management, and outcomes of ophthalmic irAEs. Medical records of 962 patients who received ICI therapy were retrospectively reviewed, and 248 patients (25.8%) experienced irAEs. The first-year incidences of total irAEs and ophthalmic irAEs were 23.5% and 1.1% respectively. The most common ICI received was pembrolizumab (38.8%).
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Dermatology
Pierre-Olivier Grenier, Lindsay McCormack, Shomoukh A. Alshamekh, Denise M. Adams, Cameron C. Trenor, Meghan J. O'Hare, Marilyn G. Liang
Summary: This case series investigates the clinical spectrum and frequency of mucocutaneous adverse events related to oral sirolimus in populations with vascular anomalies. The study found a wide range of mucocutaneous adverse reactions caused by oral sirolimus in patients with vascular anomalies, with a relatively high frequency.
Article
Allergy
Anna Kychygina, Myriam Cassagne, Marie Tauber, Stephane Galiacy, Carle Paul, Pierre Fournie, Michel Simon
Summary: Dupilumab is a new biological therapy for atopic diseases, which has shown effectiveness in treating atopic dermatitis, asthma, and chronic rhinosinusitis. However, it is associated with various adverse events including injection-site reactions, ophthalmic complications, dermatitis, psoriatic lesions, lymphoma exacerbation, alopecia areata, hypereosinophilia, and arthritis. The molecular origin of these adverse events is unclear and further research is needed.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
(2022)
Article
Clinical Neurology
Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
Summary: In primary progressive MS (PPMS) patients, smoking was found to be associated with disability worsening, while obesity showed no significant correlation. Over three years of follow-up, smoking and BMI were not linked to physical and cognitive disability worsening risk.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Carlos Camara-Lemarroy, Claudia Silva, Jit Gohill, V. Wee Yong, Marcus Koch
Summary: In this cohort of patients with inactive PPMS, HCQ treatment attenuated the increase of NfL and GFAP after 6 months of treatment and up to 18 months of follow-up, suggesting a treatment effect of HCQ over these biomarkers. RNFL thickness, a marker of neuroaxonal atrophy, was associated with disability worsening and should be explored further as a prognostic marker in this population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Anibal Chertcoff, Huah Shin Ng, Fong Zhu, Yinshan Zhao, Helen Tremlett
Summary: This study estimated the prevalence of polypharmacy in individuals with multiple sclerosis (MS) and compared the characteristics of those with and without polypharmacy. The results showed that more than one in four MS patients met the criteria for polypharmacy. The likelihood of polypharmacy was higher in women, older individuals, those with multiple comorbidities, and lower socioeconomic status.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Floriane Calocer, Huah Shin Ng, Feng Zhu, Yinshan Zhao, Olivier Dejardin, Emmanuelle Leray, Gilles Defer, Charity Evans, John D. Fisk, Ruth Ann Marrie, Helen Tremlett
Summary: The study found that lower socioeconomic status is associated with a higher mortality risk in persons with multiple sclerosis (PwMS).
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Fardowsa L. A. Yusuf, Jose M. A. Wijnands, Mohammad Ehsanul Karim, Elaine Kingwell, Feng Zhu, Charity Evans, John D. Fisk, Yinshan Zhao, Ruth Ann Marrie, Helen Tremlett
Summary: Sex and age differences in healthcare utilization were observed during the prodromal phase of multiple sclerosis. Males and older individuals had higher rates of healthcare utilization and were more likely to visit general practitioners, while younger individuals were more likely to visit ophthalmologists. However, no significant sex and age differences were found in the smaller clinical cohort.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Marcus W. Koch, Pavle Repovic, Jop Mostert, James D. Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
Summary: This study used patient-level data from two large randomized controlled trials to investigate the performance of alternative scoring methods for the nine-hole peg test (NHPT) in progressive multiple sclerosis (MS). The results showed that the standard NHPT and dominant hand (DH) or non-dominant hand (NDH) alternatives had minimal change, while the NHPT using either hand (EH) resulted in more worsening events. Non-ambulatory patients with progressive MS had more NHPT worsening, especially when using the EH NHPT. Therefore, NHPT can be used as the primary outcome measure in clinical trials involving non-ambulatory patients, but further research is needed to assess its precision in this population.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Marcus W. Koch, Pavle Repovic, Jop Mostert, James D. Bowen, Jacynthe Comtois, Eva Strijbis, Bernard Uitdehaag, Gary Cutter
Summary: This study investigates the short-term variation in T25FW and NHPT using patient-level original trial data and compares it with disability change at 12-month follow-up in people with PPMS. The traditional =20% change threshold for T25FW and NHPT represents a reasonable compromise between reducing false change events and achieving a large number of change events during follow-up.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Ugo Fedeli, Claudio Barbiellini Amidei, Francesco Avossa, Elena Schievano, Elaine Kingwell
Summary: People with multiple sclerosis have a higher risk of death from infections, especially influenza, pneumonia, and urinary tract infections. The number of deaths related to COVID-19 did not significantly differ between those with and without multiple sclerosis, but there were peaks in MS-related deaths during the pandemic.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Eline Coerver, Sophie Janssens, Aroosa Ahmed, Mark Wessels, Zoe van Kempen, Bas Jasperse, Frederik Barkhof, Marcus Koch, Jop Mostert, Bernard Uitdehaag, Joep Killestein, Eva Strijbis
Summary: Inflammatory disease activity in multiple sclerosis (MS) decreases with advancing age, and this study investigated the relation between age and MRI measures of inflammatory disease activity in a real-world cohort of people with relapse onset MS.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Nina Castrogiovanni, Jop Mostert, Pavle Repovic, James D. D. Bowen, Bernard M. J. Uitdehaag, Eva M. M. Strijbis, Gary R. R. Cutter, Marcus W. W. Koch
Summary: This study used data from a large clinical trial to describe the change in Symbol Digit Modalities Test (SDMT) and Paced Auditory Serial Addition Test (PASAT) over up to 144 weeks of follow-up. The findings showed that both SDMT and PASAT scores steadily improved throughout the follow-up period, most likely due to a practice effect. Therefore, caution should be exercised when interpreting these cognitive outcome measures as longitudinal outcomes in clinical trials.
Article
Clinical Neurology
Fardowsa L. A. Yusuf, Ayesha Asaf, Ruth Ann Marrie, Ping Li, Kyla McKay, Yinshan Zhao, Feng Zhu, Colleen Maxwell, Helen Tremlett
Summary: Canada has one of the highest rates of paediatric-onset multiple sclerosis (PoMS) globally, and the prevalence, but not incidence, has increased over time. Allocation of resources to support the growing youth population with MS should be a priority.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Meeting Abstract
Clinical Neurology
H. Yong, I. E. Tottenham, C. Silva, M. W. Koch, C. Camara-Lemarroy
MULTIPLE SCLEROSIS JOURNAL
(2023)
Meeting Abstract
Clinical Neurology
F. L. A. Yusuf, J. M. A. Wijnands, M. E. Karim, E. Kingwell, F. Zhu, C. Evans, J. D. Fisk, Y. Zhao, R. A. Marrie, H. Tremlett
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
H. Tremlett
MULTIPLE SCLEROSIS JOURNAL
(2022)
Meeting Abstract
Clinical Neurology
F. La Yusuf, A. Asaf, P. Li, K. A. Mckay, Y. Zhao, F. Zhu, H. Tremlett, R. A. Marrie, C. Maxwell
MULTIPLE SCLEROSIS JOURNAL
(2022)